Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant
Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment. Cancer Res; 76(15); 4579-91. ©2016 AACR..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Cancer research - 76(2016), 15, Seite 4579 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Richmond, Jennifer [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| RVK: |
|---|
| doi: |
10.1158/0008-5472.CAN-16-0523 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1980294542 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1980294542 | ||
| 003 | DE-627 | ||
| 005 | 20230513005345.0 | ||
| 007 | tu | ||
| 008 | 160816s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-16-0523 |2 doi | |
| 028 | 5 | 2 | |a PQ20160815 |
| 035 | |a (DE-627)OLC1980294542 | ||
| 035 | |a (DE-599)GBVOLC1980294542 | ||
| 035 | |a (PRQ)c694-bf5460f3ec0c4e40c9183bdebabcc80005d042e5d50e8cdd0adae7b8c14999e30 | ||
| 035 | |a (KEY)0108894720160000076001504579acutesensitivityofphlikeacutelymphoblasticleukemia | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a XA 10000 |q AVZ |2 rvk | ||
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Richmond, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment. Cancer Res; 76(15); 4579-91. ©2016 AACR. | ||
| 540 | |a Nutzungsrecht: © 2016 American Association for Cancer Research. | ||
| 700 | 1 | |a Robbins, Alissa |4 oth | |
| 700 | 1 | |a Evans, Kathryn |4 oth | |
| 700 | 1 | |a Beck, Dominik |4 oth | |
| 700 | 1 | |a Kurmasheva, Raushan T |4 oth | |
| 700 | 1 | |a Billups, Catherine A |4 oth | |
| 700 | 1 | |a Carol, Hernan |4 oth | |
| 700 | 1 | |a Heatley, Sue |4 oth | |
| 700 | 1 | |a Sutton, Rosemary |4 oth | |
| 700 | 1 | |a Marshall, Glenn M |4 oth | |
| 700 | 1 | |a White, Deborah |4 oth | |
| 700 | 1 | |a Pimanda, John |4 oth | |
| 700 | 1 | |a Houghton, Peter J |4 oth | |
| 700 | 1 | |a Smith, Malcolm A |4 oth | |
| 700 | 1 | |a Lock, Richard B |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d Birmingham, Ala. [u.a.] : AACR, 1941 |g 76(2016), 15, Seite 4579 |w (DE-627)12906775X |w (DE-600)1432-1 |w (DE-576)014399199 |x 0008-5472 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2016 |g number:15 |g pages:4579 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1158/0008-5472.CAN-16-0523 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/27302164 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_55 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2219 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 10000 |
| 936 | b | k | |a 44.81 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 76 |j 2016 |e 15 |h 4579 | ||